

Invitation to presentation of Xbrane Biopharma's Year-end report 2019 on February 28, 2020

Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on February 28th, 2020, at 10.00 a.m. CET. Xbrane will publish the company's Year-end report for 2019, on Friday February 28th, 2020, at 8.00 a.m. CET.

Martin Åmark, CEO, and Susanna Helgesen, CFO, will present Xbrane and comment on the Year-end report for 2019, followed by a Q&A session. The presentation will be in English. To attend, please dial-in at one of the numbers below:

Standard international: +44 (0) 2071 928 000

UK (Local): +44 (0) 844 571 88 92

UK (Toll free): 08 003 767 922

Sweden (Local): +46 (0) 850 692 180

Sweden (Toll free): 020 012 55 81

US (Local): +1 631 510 74 95

US (Toll free): +1 866 966 13 96

Confirmation Code: 78 85 179

Web link:

<https://edge.media-server.com/mmc/p/awbtgry7>

Contacts

Martin Åmark, CEO

M: +46 (0) 763-093 777

E: martin.amark@xbrane.com

Susanna Helgesen, CFO

M: +46 (0) 708-278 636

E: susanna.helgesen@xbrane.com

About Us

Xbrane is a commercial phase Swedish biopharmaceutical company that develop and produces biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane's headquarter is located in Solna outside of Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq Stockholm since September 2019 with the ticker XBRANE. For more information please visit www.xbrane.com.

Press Release
26 February 2020 15:00:00 CET



Attachments

[Invitation to presentation of Xbrane Biopharma's Year-end report 2019 on February 28, 2020](#)